Investment Rating - The report recommends a positive investment outlook for the company, highlighting its strategic transition towards a dual-platform model combining ICL and CRO services [22]. Core Insights - The company has demonstrated resilience in its revenue streams, with a notable 30% year-on-year growth in its co-construction business and an 18% increase in CRO revenue, despite an overall revenue decline of 13.3% due to industry adjustments [21]. - The strategic acquisition of Crown Bioscience for approximately $204 million is expected to enhance the company's capabilities in drug development and clinical research, marking a significant shift from a traditional medical diagnostics provider to a comprehensive laboratory service provider [3][11]. - The company is focusing on expanding its high-end testing services and enhancing operational efficiency through AI and lean management practices, which have already resulted in a 13% reduction in reagent procurement costs and an 11% increase in laboratory efficiency [21][18]. Summary by Sections Financial Performance - In the first half of 2025, the company reported total revenue of 1.27 billion RMB, a decrease of 13.3% year-on-year. However, the co-construction business saw a 30% increase in revenue, with a four-year compound annual growth rate (CAGR) of 48% [2][7]. - The CRO business also experienced an 18% revenue growth, with new contract values exceeding 24 million RMB [11]. Business Segments - The ICL segment remains a cornerstone of the company's operations, providing over 4,000 medical testing services across various disease areas, with a focus on infection, oncology, and hematology [4]. - The special testing segment is identified as a key growth driver, with a projected revenue growth of over 18% for 2024, particularly in oncology testing, which is expected to grow by 47% [5][6]. Strategic Initiatives - The company is enhancing its special testing capabilities through strategic partnerships and acquisitions, including the acquisition of Yuan De You Qin, a leading blood disease diagnostics company [6]. - The co-construction business model is evolving into a strategic partnership with hospitals, creating a robust service barrier and strong customer loyalty [7][8]. Market Outlook - The ICL market in China is projected to reach 51.3 billion RMB by 2026, with a CAGR of 18.2% from 2021 to 2026, driven by increasing outsourcing demands from hospitals [15]. - The CRO market is also expected to grow significantly, with forecasts indicating a market size of 528.6 billion RMB in China by 2026 [17]. Competitive Advantages - The company boasts a leading laboratory network and R&D capabilities, supported by advanced operational management and logistics systems, which create a strong competitive moat in the independent medical laboratory industry [18]. - The integration of AI in drug discovery and clinical research processes is enhancing operational efficiency and creating new commercial opportunities [13][19]. Future Plans - The company aims to transition from traditional ICL services to a comprehensive healthcare service platform, focusing on quality improvements and expanding its market share in high-end testing and CRO services [20].

新加坡證券交易所有限公司、香港交易及結算所有限公司及香港聯合交易所有限公司對本公告 的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 ISDN HOLDINGS LIMITED 億仕登控股有限公司 （於新加坡註冊成立的有限公司） （香港股份代號：1656） （新加坡股份代號：I07.SI） 海外監管公告 億仕登旗下NovaPeak與Panasonic HD達成合作， 共同推動LiveInspect.AI全球佈局 本海外監管公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條之規定作出。 請參閱以下億仕登控股有限公司（「本公司」）於2026年3月13日於新加坡證券交易所 有限公司網頁發表之公告。 承董事會命 億仕登控股有限公司 常務董事兼總裁 張子鈞 香港，2026年3月13日 於本公告日期，本公司董事會包括本公司執行董事張子鈞先生及孔德揚先生；本公司非 執行董事 Toh Hsiang-Wen Keith 先生；以及本公司獨立非執行董事陳順亮先生（主 席）、蘇健興先生及王素玲女士。 業務動態更新 億仕登 ...

一旦掌握這7個人生複利公式，你的人生將開始快速成長 https://youtu.be/Uz0awqTLJeA 會員頻道的內容會依照這7個公式，一步步陪你實踐 👉 加入會員頻道，從第1個公式開始實踐：https://bit.ly/goldenrich-members ☕️ 如果你想免費支持我們，這裡有個簡單的方法： 👉 https://bit.ly/GET-IBKR 🙏 點擊連結沒有任何費用，每次點擊都能幫助支持我們的頻道。IB盈透證券：全球領先、備受信賴的投資平台，交易覆蓋150個市場，低成本、資金靈活，是多元化投資的理想選擇！ (Disclosures: https://bit.ly/content-disclosure) 你只剩5年可以變有錢！｜AI時代最大的紅利假象 今天這一期節目，我們想跟大家分享一個很有意思、但也有點讓人不安的理論。這個理論的核心很直接：你可能只剩下大概五年的窗口期，去完成一次真正的財富跨越。因為一旦人工智慧發展到某個臨界點，當AI變成人人都能用、而且幾乎什麼都做得到的工具時，如果你還沒有提前卡位，那你很可能就會被鎖在現在的經濟層級，很難再往上移動。 🔔 貼心提醒 訂閱後不要忘記按旁 ...

（於百慕達註冊成立的有限公司） （股份代號：00499） 供股所得款項用途的最新變動之補充公佈 茲提述青島控股國際有限公司（「本公司」，連同其附屬公司統稱「本集團」）於 2022年6月30日、2022年7月19日、2023年3月28日、2024年8月7日及2025年11月17日 刊發的公佈（「該等公佈」）以及本公司2024年年度報告（「2024年年報」）。除非本 公佈另有界定，本公佈所用詞彙具有該等公佈界定的相同涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 QINGDAO HOLDINGS INTERNATIONAL LIMITED 青島控股國際有限公司* – 1 – 科技業務的初期重點領域包括(i)消費者電子產品；(ii)汽車電子產品；及(iii)人工智 慧相關產品。主要產品類別包括電子元件，尤其專注於被動元件（包括電感器及電 容器）、電力裝置及存儲芯片。 業務營運及收益來源 本公司將透過其全資附屬公司意柏發展有限公司（「意柏」）拓展科技 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 CBK Holdings Limited 漢諾佳池控股有限公司 （前 稱 為CBK Holdings Limited國 茂 控 股 有 限 公 司） （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：8428） 內幕消息 有 關 業 務 營 運 及 復 牌 進 度 的 季 度 更 新；及 繼續暫停買賣 本公告乃由漢諾佳池控股有限公司（「本公司」，連 同 其 附 屬 公 司，統 稱「本集團」） 董 事（「董 事」）會（「董事會」）根據香港聯合交易所有限公司（「聯交所」）GEM證券上 市規則（「GEM上市規則」）第17.10條及香港法例第571章證券及期貨條例第XIVA 部項下內幕消息條文（定 義 見GEM上 市 規 則）而 作 出。 茲 提 述 本 公 司 日 期 為 二 零 二 五 年 六 月 二 十 六 日、二 零 二 ...

Core Viewpoint - The long-term bullish logic for silver remains intact, but multiple short-term risks are emerging that could lead to a significant correction from year-end to early next year [1] Short-term Negative Factors - Five short-term bearish factors that may pressure silver prices are identified: 1. Year-end and early-year selling triggered by tax considerations 2. Short-term rebound risk of the US dollar 3. Increased margin requirements by exchanges suppressing leverage demand 4. Technical indicators entering overbought territory 5. Rising narratives of copper as a substitute for silver [1] Long-term Outlook - Despite the short-term headwinds, the long-term outlook for silver remains bullish due to the ongoing expansion of electricity demand in solar energy, data centers, and artificial intelligence [1] - Short-term corrections may provide a window for long-term investors to reposition [1]

Market Overview - The Hang Seng Index (HSI) has recently surged to around 26,000 points, with investors primarily using bull and bear certificates to navigate market volatility [1][2] - The concentration of bull certificates is around 25,100 to 25,200 points, with a total of approximately 1,600 contracts, indicating a bullish sentiment among investors [1] Investment Products - Investors are utilizing various products such as bull and bear certificates, with specific recommendations including bull certificate 64550 (redemption price at 25,800) and bear certificate 55898 (redemption price at 26,200) [2] - The market also offers call and put warrants, with notable options like call warrant 19861 (exercise price at 27,100, expiring February next year) and put warrant 21317 (exercise price at 25,670, expiring March next year) [2] Company Analysis: Alibaba (9988) - Alibaba reported a 72% year-on-year decline in quarterly profit, amounting to 10.4 billion RMB, which was slightly below market expectations, leading to downward pressure on its stock price [3] - The current stock price of Alibaba is around 155 RMB, with investors showing interest in call warrants ahead of earnings announcements [3][4] - Recommended products include call warrant 20577 (exercise price at 173.43, expiring April next year) and put warrant 20718 (exercise price at 142.78, expiring March next year) [4] Company Analysis: Meituan (3690) - Meituan's stock price has increased significantly, attributed to management's indication of potentially reducing aggressive pricing strategies due to substantial losses [5] - The stock price has rebounded nearly 6% to around 104 RMB, with investors optimistic about the future [5] - Suggested products include call warrant 20815 (exercise price at 123.79, expiring June next year) and put warrant 20135 (exercise price at 67.88, expiring March next year) [5] Company Analysis: Xiaomi (1810) - Xiaomi's stock price has risen following a significant investment from CEO Lei Jun, who purchased 100 million RMB worth of shares, indicating confidence in the company's future [6] - The stock price has rebounded to around 40 RMB, with investors considering it a potential bottom [6] - Recommended products include call warrant 22713 (exercise price at 62.05, expiring May next year) and put warrant 22168 (exercise price at 32.18, expiring June next year) [6] Company Analysis: Pop Mart (9992) - Pop Mart's stock has seen a recovery from a low of around 192 RMB to approximately 205 RMB, as investors believe the price adjustment has been sufficient [7] - Suggested products include call warrant 22285 (exercise price at 260.12, expiring April next year) and put warrant 20663 (exercise price at 199.9, expiring February next year) [7]

Group 1 - Jiangsu Hongxin's stock price increased by over 43%, reaching 4.80 HKD with a trading volume of 14.57 million HKD [1] - The company announced a placement of up to 21.42 million new shares, representing a 9.09% increase in post-expansion share capital, at a placement price of 2.90 HKD, which is a 13.95% discount to the closing price on November 11 [1] - The total fundraising amount is 62.13 million HKD, with a net amount of 58.65 million HKD intended for investment in Haike Hongxin [1] Group 2 - Haike Hongxin primarily engages in digital technology services, including artificial intelligence, smart robotics, software, and blockchain solutions development and application [1] - Its business scope also includes data processing, e-commerce, import and export, advertising, and related consulting and technical services [1] - The board believes that the placement will broaden the company's shareholder and capital base, and the net proceeds will strengthen the group's financial position for future development [1]

Core Viewpoint - Jiangsu Hongxin (02625) shares rose over 16%, reaching a price of HKD 3.93, with a trading volume of HKD 3.4448 million [1] Group 1: Share Placement - Jiangsu Hongxin announced a placement of up to 21.4246 million new shares, representing a 9.09% increase in the enlarged share capital [1] - The placement price is set at HKD 2.9, which reflects a discount of 13.95% compared to the closing price on November 11 [1] - The total amount raised from the placement is HKD 62.13 million, with a net amount of HKD 58.65 million intended for investment in Haike Hongxin [1] Group 2: Business Focus - Haike Hongxin primarily engages in digital technology services, including artificial intelligence, smart robotics, software, and blockchain solutions development and application [1] - Its business scope also includes data processing, e-commerce, import and export, advertising, and related consulting and technical services [1] Group 3: Financial Strategy - The board believes that the placement will broaden the company's shareholder and capital base [1] - The net proceeds from the placement will strengthen the group's financial position and prepare for future development [1]

Group 1 - The company Jiangsu Hongxin (02625.HK) has entered into a placement agreement to issue up to 21,424,691 new H shares at a price of HKD 2.90 per share, representing a discount of approximately 13.95% compared to the closing price of HKD 3.37 on the date of the agreement [1] - The placement shares will account for 10% of the company's existing share capital and approximately 9.09% of the enlarged share capital post-placement, assuming no changes in the issued share capital until the completion of the placement [1] - The estimated net proceeds from the placement, after deducting commissions and other expenses, are expected to be around HKD 58.65 million, equating to a net placement price of approximately HKD 2.737 per share [1] Group 2 - The net proceeds from the placement are intended to be fully invested in Haike Hongxin Digital Technology (Jiangsu) Co., Ltd., which focuses on digital technology services, including artificial intelligence, smart robotics, software, and blockchain solutions [2] - Haike Hongxin's business also encompasses data processing, e-commerce, import and export, advertising, and related consulting and technical services [2]